Benzinga | Nov 10, 2021 07:53AM EST

VYNE Therapeutics Q3 EPS $(0.36) Misses $(0.32) Estimate, Sales $4.09M Miss $4.76M Estimate

VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.32) by 12.5 percent. This is a 30.77 percent increase over losses of $(0.52) per share from the same period last year. The company reported quarterly sales of $4.09 million which missed the analyst consensus estimate of $4.76 million by 14.16 percent. This is a 24.99 percent increase over sales of $3.27 million the same period last year.